Wellcome invests $38M in another gene therapy startup, targeting hemophilia

Damian Garde

The Trust's investment arm is putting up £25 million ($ 38 million) to launch a new company developing a potential one-time treatment for and planning to build a pipeline of therapies.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS